Floatz logo

RHENIUM RE-188 P2045

Small Cell Lung Cancer (SCLC)

University of Maryland, Baltimoreprotein_peptidePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

291 Active assets in the Small Cell Lung Cancer (SCLC) cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

RHENIUM RE-188 P2045 is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
large cell neuroendocrine carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →